Nippon Shinyaku Co., Ltd. (4516)

Name: Nippon Shinyaku Co., Ltd. (4516) — historial de estados financieros
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.

Healthcare · Wall Street (EE. UU.) · Última actualización: 2026-10-02

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Atthena Therapeutics, Inc.

Cifras clave

Capitalización bursátil: JPY 228 billion
Ingresos (ejercicio cerrado en 2026-03-31): JPY 170.8B
Beneficio neto: JPY 29.7B
Margen bruto: 66.4%
Margen neto: 17.4%

Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →

Cuenta de resultados anual

Cuenta de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Ingresos totales	JPY 170.8B	JPY 160.2B	JPY 148.3B	JPY 144.2B
Beneficio bruto	JPY 113.3B	JPY 109.1B	JPY 98.0B	JPY 88.2B
Ingresos operativos (EBIT)	JPY 35.5B	JPY 35.5B	JPY 33.3B	JPY 30.1B
Ingresos netos	JPY 29.7B	JPY 32.6B	JPY 25.9B	JPY 22.8B

Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.

Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de 4516. /companies/us/4516

Empresas similares

La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.

English version →Todas las acciones

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.